Search
Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today
The Robert Connor Dawes Foundation has joined forces with the Ethan Davies Fellowship to co-fund a The Kids Research Institute Australia initiative aimed at uncovering new treatments for aggressive childhood brain tumours.
Kids born with Down syndrome are at high risk of an array of health problems. One of the lesser-known complications is their increased risk of childhood leukaemia.
Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award
Dr Sébastien Malinge has received a Stan Perron Charitable Foundation Research Fellowship for his pioneering research, which is paving the way for safer, targeted therapies for children with hard-to-treat leukaemia
Cancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.
Four The Kids Research Institute Australia-based biobanks which underpin a range of cancer, respiratory and early life research have received more than $450,000 in funding.
The generous support of West Australians through Channel 7’s Telethon Trust will help support crucial child health research at The Kids Research Institute Australia in 2022.
Invasive pulmonary aspergillosis remains a major cause of morbidity and mortality for immunocompromised children, particularly for patients with acute leukaemia and those undergoing haematopoietic stem cell transplantation. Timely diagnosis, using a combination of computed tomography (CT) imaging and microbiological testing, is key to improve prognosis, yet there are inherent challenges in this process. For CT imaging, changes in children are generally less specific than those reported in adults and recent data are limited.
Invasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.